Stay updated on Pembrolizumab and Binimetinib in TNBC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Binimetinib in TNBC Clinical Trial page.

Latest updates to the Pembrolizumab and Binimetinib in TNBC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe ClinicalTrials.gov record for Mayo Clinic’s pembrolizumab and binimetinib breast cancer study is displayed, including study details, eligibility criteria, outcomes, and a linked protocol document.SummaryDifference58%

- Check15 days agoChange DetectedThe site footer revision changed from v3.7.2 to v3.8.0 while the study page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check22 days agoChange DetectedA site-wide NIH banner announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs. The clinical trial record itself remains unavailable.SummaryDifference1%

- Check29 days agoChange DetectedThe footer’s ClinicalTrials.gov revision label changed from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check36 days agoChange DetectedThe footer revision identifier changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check57 days agoChange DetectedThe page now shows a 403 Forbidden error page, replacing the expected study content with a standard error screen. The header and footer are visible, and the 403 message appears in the main area.SummaryDifference20%

Stay in the know with updates to Pembrolizumab and Binimetinib in TNBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Binimetinib in TNBC Clinical Trial page.